Skip to main content
XERS logo

XERS · Xeris Biopharma Holdings, Inc. · Holdings

Track XERS — free
$11.18 +0.23 (+2.14%)
Market Cap
$2.05B
Shares
182.32M
Volume · Oct 20 2.9M Avg daily vol (3M) 2.29M

Institutional ownership from SEC Form 13F filings. Investment managers with more than $100 million in U.S. equities must disclose their positions every quarter, within 45 days of quarter-end, so the holdings shown can lag the market by up to a quarter.

Institutional holdings are being reconciled with SEC filings. Holder totals and changes may be incomplete until reconciliation finishes.
The Sep 30, 2026 filing window is still open — showing the latest known positions. Funds that have not filed yet carry their prior-quarter positions; a fund that filed without this stock counts as sold out. Each fund's Change is measured against its own previous reported quarter, shown in the Reported column. Pick a completed quarter in the Quarter selector below to put every fund on one quarter and see the stock-wide activity breakdown.
Holders: 242
Total Value: $879,411,570
Total Shares: 110,559,195
Showing 1–100 of 249 holdings by value · page 1 of 3

Institutional Ownership Trend

21 quarters

Holder Concentration

Across 241 13F filers
Top Holder
13.2%
Sep 2023 → Jun 2026 · range 12.1% – 17.0%
of institutional value
Top 5
35.7%
Sep 2023 → Jun 2026 · range 34.1% – 57.5%
of institutional value
Top 10
49.6%
Sep 2023 → Jun 2026 · range 48.8% – 75.2%
of institutional value
HHI
397
Sep 2023 → Jun 2026 · range 373 – 803
Broadly held

Who Holds XERS

Last 8 quarters through Sep 30, 2026 (filing window open)

Each kind of 13F filer's share of the common shares 13F filers report. Holder type comes from regulatory records, never the filer's name; style, turnover and horizon are measured from each filer's own 13F book. The quarter selector does not change this card.

Jun 30, 2026, the newest closed quarter: 240 filers, like-for-like change +2.2%; actively managed books -3.3%; index-like books +10.1%.

Holder type Share Filers Change
Registered adviser 38.9% 125 +0.9%
Exempt adviser 3.1% 5 -22.6%
Adviser 1.7% 7 +45.2%
Bank 10.3% 12 +11.8%
Insurer 0.2% 2 -3.8%
Broker-dealer 0.3% 2 +14.0%
Benefit plan 0.6% 5 +22.6%
Non-US 2.1% 8 -18.1%
Holding company 20.2% 8 +9.2%
Unknown 22.5% 66 -2.0%

The Sep 30, 2026 filing window is still open, so its bar carries the Jun 30, 2026 positions of filers that have not filed yet.

How the mix is measured

Shares are 13F common shares restated to today's split basis; options and principal amounts are left out. The change compares only filers with a 13F in both quarters and keeps each filer in its bucket of the later quarter on both sides; a filer that continues under a new CIK is compared through its successor. Holder type comes from each filer's current regulatory profile; client base and private funds come from the Form ADV roster current at each quarter end (rosters from December 2019, so an earlier quarter reads Unknown). Style, turnover, horizon and book size are measured from each filer's 13F book in the newest measured quarter, and Not measured means none was. Actively managed books are those measured systematic-like, concentrated or diversified active.

Excluded 3 holders with no observed 2026-03-31 13F and 3 holders with no observed 2026-06-30 13F. Compared across CIK changes: JANUS HENDERSON GROUP PLC continues as Jupiter Topco LLC.

Conviction and Crowding

240 13F filers, quarter ended Jun 30, 2026

Measured across every 13F filer's common-share book once the quarter's filing window closed. Crowding counts filers with high turnover or that advise private funds on Form ADV.

Conviction holders
3
1.25% of filers hold it in their top 10
Mar 31, 2026: 3
Holders above 5%
2
median weight 0.001%
Mar 31, 2026: 2
Crowding
19.8%
of shares outstanding, 58th percentile
Mar 31, 2026: 21.1%
Private-fund advisers
14.5%
of shares outstanding
Institutional ownership
62.7%
66.5% of the estimated free float
Top 10 holders
50.2%
of 13F shares, Herfindahl 0.041
Active holders
-3.3%
like-for-like share change of active filers
5% stakes on record
3
0 13D, 3 13G (3 institutional, 0 passive, 0 exempt)
How long holders have held it value-weighted 10.2 quarters
Under 1 year 21.0% 1 to 3 years 44.3% 3 years or more 34.7% Since coverage start 0.000%

Managers in the top fifth by current three-year FundScore alpha were net buyers of $0 (0 buying, 0 selling).

Estimated Holder Cost Basis

Quarter ended Jun 30, 2026, on that quarter's share basis

Estimated, never filed: each 13F buy is costed at its quarter's average traded price and each sale keeps the average cost, so this is what holders paid on average if they traded evenly through each quarter.

Estimated avg cost
$4.76
estimated per share
Mar 31, 2026: $4.64
Quarter-end price
$7.92
implied by 13F values
Estimated gain or loss
+66.5%
price against the estimated cost
Estimated at a loss
0.000%
of costed 13F value

Estimated cost covers 84.5% of the 13F shares; positions already held when a filer's 13F history starts, or bought in a quarter without a trusted average price, have no estimate.

Shared Holders

Companies XERS's active holders also own, quarter ended Jun 30, 2026
# Company Shared holders
1 AGIO Agios Pharmaceuticals, Inc. 7
2 TVTX Travere Therapeutics, Inc. 7
3 ANNX Annexon, Inc. 5
4 VSTM Verastem, Inc. 4
5 CNTB Connect Biopharma Holdings Ltd 3
6 EWTX Edgewise Therapeutics, Inc. 5
7 NUVB Nuvation Bio Inc. 4
8 SPRB Spruce Biosciences, Inc. 3
9 KURA Kura Oncology, Inc. 4
10 BCYC Bicycle Therapeutics PLC 3

Shareholder Targets

13F filers that own its peers but not XERS, quarter ended Jun 30, 2026

Found through its holder-overlap peers: AGIO, TVTX, ANNX, VSTM, CNTB, EWTX, NUVB, SPRB, KURA, BCYC, SIBN, MGTX, ZYME, ANRO, SYRE, VRDN, ORKA, RARE, FDMT, DYN. 630 filers in all.

# Filer In peers
1 Paradigm Biocapital Advisors LP Registered adviser, Concentrated $1,083,648,730 4 held
2 RTW INVESTMENTS, LP Registered adviser, Diversified active $968,248,044 5 held
3 T. Rowe Price Investment Management, Inc. Adviser, Diversified active $858,042,148 4 held
4 Venrock Adviser, LLC Registered adviser, Concentrated $781,179,507 5 held
5 ORBIMED ADVISORS LLC Registered adviser, Diversified active $750,884,467 6 held
6 EcoR1 Capital, LLC Registered adviser, Concentrated $600,445,942 1 held
7 ADAGE CAPITAL PARTNERS GP, L.L.C. Registered adviser, Diversified active $559,082,702 10 held
8 RA CAPITAL MANAGEMENT, L.P. Registered adviser, Concentrated $556,109,675 3 held
9 Driehaus Capital Management LLC Registered adviser, Diversified active $535,258,241 4 held
10 Capital World Investors Adviser, Diversified active $529,308,778 2 held

Fund Ownership of XERS by Fund Type

Registered funds' Form N-PORT reports for the quarter ended Jun 30, 2026

Index funds and index ETFs hold 13.35% of shares outstanding.

Fund type Of shares outstanding Shares
Index funds 3.08% 5,616,854
Index ETFs 10.27% 18,718,814
Active ETFs 0.67% 1,228,525
Active funds 4.98% 9,082,594
Unclassified 0.42% 765,460
All registered funds 19.42% 35,412,247
How fund types are measured

Each fund series counts once, with its latest Form N-PORT report dated inside the quarter; only long share positions count, restated to today's split basis. The fund type is the series' latest Form N-CEN answer on or before the quarter end (the index-fund box and the exchange-traded flag), never its name. Unclassified funds have no usable N-CEN; unit investment trusts are among them, so index ownership is a floor. Funds sit inside their advisers' 13F reports, so these shares overlap the 13F figures and are never added to them.

Showing 100 of 249
Export CSV
Holder Value (USD) % of 13F Shares Open

Showing the top 100 of 249 holders. Create a free account to see every holder, past quarters, search, filters and CSV export.

Key facts CIK 1867096 CUSIP 98422E103 13F (30d) 18 filings 18 filers Visit website Investor relations